XERS Xeris Biopharma Holdings Forecast, Technical & Fundamental Analysis
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States... Show more
XERS is expected to report earnings to fall 120.50% to 3 cents per share on November 05
Q3'26
Est.
$0.04
Q2'26
Missed
by $0.19
Q4'25
Beat
by $0.04
Q3'25
Missed
by $0.01
Q2'25
Beat
by $0.02
The last earnings report on August 06 showed earnings per share of -18 cents, missing the estimate of 0 cents. With 885.79K shares outstanding, the current market capitalization sits at 1.46B.
A.I. Advisor
published General Information
General Information
a developer of ready-to-use, liquid-stable injectables
A.I.dvisor indicates that over the last year, XERS has been loosely correlated with MIRM. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if XERS jumps, then MIRM could also see price increases.
XERS sees its 50-day moving average cross bullishly above its 200-day moving average
The 50-day moving average for XERS moved above the 200-day moving average on July 20, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where XERS's RSI Indicator exited the oversold zone, of 36 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 56 cases where XERS's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
XERS moved above its 50-day moving average on August 07, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where XERS advanced for three days, in of 249 cases, the price rose further within the following month. The odds of a continued upward trend are .
XERS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In of 228 cases where XERS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on July 28, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on XERS as a result. In of 84 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for XERS turned negative on July 20, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 41 similar instances when the indicator turned negative. In of the 41 cases the stock turned lower in the days that followed. This puts the odds of success at .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where XERS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. XERS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock slightly better than average.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (107.527) is normal, around the industry mean (40.267). P/E Ratio (115.929) is within average values for comparable stocks, (102.305). XERS's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.202). XERS has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.033). P/S Ratio (4.303) is also within normal values, averaging (114.263).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
